25, January 2017

Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide further details of patient participation following confirmation (as announced on 22 December 2016) that the Company had successfu...

Click here for more details

24, January 2017

Change of Adviser

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect....

Click here for more details